Background: Visceral leishmaniasis (VL) is a neglected tropical disease resulting in a huge 9 burden of mortality and impact on development of a country. Even though anti-leishmanial 10 drugs reduce the incidence of mortality among VL patients, still there is a death of VL patients 11 while on treatment. However, study on incidence of mortality and its predictors among these 12 patients while on treatment is scarce in Ethiopia.
Introduction
7 137 spleen size regression), and/or has a negative parasitological test of cure (TOC).
138
Treatment failure: defined as a positive TOC (parasitological failure) and/or persisting 139 clinical signs/symptoms at the end of treatment or failure to continue first-line treatment for 140 safety reasons.
141
Loss to follow up: A patient who started VL treatment but interrupted treatment due to the 142 patient leaving the Hospital during the study period [9, 15, 31] . Relapse VL: a patient with a history of previous VL and discharged improved or with a 148 negative test of cure (TOC) after treatment and who then presents with symptoms of VL after 149 four weeks of initial VL treatment and is parasitologically confirmed and documented as 150 relapse VL [32] .
151
High parasite load is parasite load grade of more than 4+ (1-10 parasites per field). Low 152 parasite load is parasite load grade of less than or equal to 3(1-10 parasites per 10-1000 fields).
153
Concomitant disease: presence of one or more of a documented case of the following 154 diseases: tuberculosis, pneumonia, malaria and HIV.
155
Toxicity during treatment: presence of one or more of documented toxicity such as cardiac 156 arrest, pancreatitis, jaundice (liver disease) and kidney failure [20] .
157
Data collection procedure and tools 158 Data were collected from VL patient charts who were registered from 2013 to 2018 using 159 pretested and structured data extraction checklist. bleeding, edema, and creatinine level were extracted at admission. The presence of toxicity 166 during treatment was also assessed. The presence or absence those abnormalities was decided 167 based on the documentation made by the physicians. Laboratory results were also collected at 168 admission and their value was compared with their reference value to decide on the presence 169 of derangement on these parameters. Patients were followed retrospectively for 12 to 28 days 170 according to their treatment category.
171

Data quality management 172
To assure the data quality, high emphasis was given in designing data collection instrument.
173
Training was given for data collectors to create a common understanding of the data extraction 174 checklist and patient chart as well as registry reviewing skills. The data extraction checklist 175 was pre-tested. Throughout the course of the data collection, data collectors were supervised 176 by the principal investigator. 258(44%) of them had more than 30 days of illness duration at admission (Table 1) . p<0.001) (Figure 2) . residence was demonstrated graphically. Accordingly, the hazards do not cross between 243 categories of jaundice and comorbidity, which means that the proportional hazard assumption 244 was satisfied for these variables. However, it crosses between categories of residence, which 245 means that proportional hazard assumption was not satisfied for residence (Figure 3) . 246 Moreover, in order to test proportional hazard assumption objectively, Schoenfeld residuals 247 test (global and scaled) was done. Accordingly, all variables with the exception of residence 248 satisfies proportional hazard assumption (p>0.05) ( This study aimed to identify incidence of mortality and its predictors among adult VL patients 280 on treatment. Accordingly, the overall incidence rate of mortality was 6.6 (95% CI 5.2 -8.4) 281 per 1000 person-days of observation, with most of deaths (60%) occurring within the first 10 282 days of follow-up period, which requires the attention of health workers in these periods.
214
283
The proportion of death among VL patients in this study was 11.09 % (95% CI: 10.85% - In the contrary, the current finding is higher than the finding of Eastern Uganda (3.7%) [6] , 298 and Northwest Ethiopia (4.8 %) [7] . The reason for this discrepancy in the case of Eastern
299
Uganda might be that only primary VL cases were included in the study, which may 300 underestimate death rate, as death is more common among relapse cases than primary VL 20 301 patients [22, 25] . In the case of earlier study of Ethiopia, VL patients who were taking 302 Amphotericin B only were included, a drug with less toxicity and more tolerability than that 303 took by participants of this study such as Sodium stibogluconate [12] .
304
In the current study, the hazard of death among relapse VL patients was 3 times higher than 305 that of primary VL patients. This finding is similar with the finding of two studies in Brazil 306 [22, 25] . This might be because of majority of the relapse cases in this study were HIV patients 307 (64%). Since both VL and HIV attack the immune system of the body, they produce a profound 
313
In our study, VL patients who had toxicity during treatment were 5.8 times more at risk of 314 mortality than those patients who had no toxicity. This finding is similar with the finding of 315 studies in Uganda, Somali and Ethiopia [6, 11, 12] . Since most anti-leishmanial drugs are toxic, 316 development of drug toxicity such as arrhythmia, pancreatitis and others is common, which 317 lead to poor compliance and further deterioration of the patient to cause death [15] .
318
The hazard of death among VL patients with comorbidity was 2.3 times higher than those 319 without comorbidity. This finding is in agreement with the finding of studies in Eastern In this study, VL patients who had jaundice at admission were 2.9 times more at risk of death 330 than their counterparts. The finding of this study is similar with studies conducted in Gedaref 331 state of Sudan, America and Brazil [5, [18] [19] [20] [21] 26 ]. This could be possibly due to, jaundice 332 (usually the sign of liver dysfunction) causes decreased plasma protein synthesis, inability to 333 detoxify drugs and impairment of other liver functions, to cause an increased risk of death.
334
Those patients who were bedridden had 3.2 times increased risk of death compared to 335 ambulatory patients. The current finding is similar with the finding of a study in Kahsay Abera 336 Hospital [9]. This might be due to majority of bedridden patients (64%) in this study had 337 concomitant diseases such as HIV/AIDS, tuberculosis and pneumonia, which ultimately 338 increases the risk of death compared to ambulatory patients. This explanation is supported by 339 studies conducted in Brazil, which states that most severely ill patients have an increased risk 340 of concomitant diseases that can increase their risk of death [18, 36] . Furthermore, severely ill 341 patients usually do not respond to their medication easily and do not take adequate food as 342 well. As limitation, since the study is retrospective, data about some variables such as blood 343 glucose level, serum albumin level and income of the patient was not collected. So we can't 344 assess the effect of these variables on the incidence of mortality.
Conclusion
346
The incidence of mortality among VL patients on treatment was high. 
